Cardior Pharmaceuticals
Non-coding RNA-based therapeutics in heart failure.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | €1.0b Valuation: €1.0b | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (8 %) | 359 % | 17 % | 18 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (8592 %) | (2261 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (6579 %) | (9031 %) | (2373 %) | (3121 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Cardior is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of innovative treatments for heart disease. The company's primary market is the medical and pharmaceutical industry, with its clients being healthcare providers and institutions seeking advanced solutions for cardiovascular conditions.
Cardior's business model revolves around the research, development, and commercialization of therapeutic solutions for heart disease. The company's main revenue stream comes from the sale of its proprietary treatments to healthcare providers. Additionally, Cardior also generates income through partnerships with other pharmaceutical companies and research institutions.
One of the company's key assets is its lead candidate, CDR132L, which is currently undergoing a Phase 2 study named HF-REVERT. This study aims to evaluate the effectiveness of CDR132L in treating heart disease. The addition of Leon Carayannopoulos, a seasoned professional in the pharma industry with a strong background in translational development and clinical pharmacology, to the Board of Directors, further strengthens Cardior's position in the market.
Cardior is also active in the conference circuit, participating in major healthcare events such as the Annual J.P. Morgan Healthcare Conference. These events provide the company with opportunities to showcase its work, network with industry professionals, and attract potential investors.
Keywords: Biotechnology, Healthcare, Heart Disease, Therapeutic Solutions, Pharmaceutical Industry, Research and Development, CDR132L, HF-REVERT Phase 2 Study, Leon Carayannopoulos, J.P. Morgan Healthcare Conference.